TREMFYA® (guselkumab) HCP

For US Healthcare Professionals

Full Prescribing Information

~90% patient retention through 2 years with TREMFYA^®1*

Patients continued therapy through Week 100 in DISCOVER 2

Patient Retention Data in DISCOVER 2 (Week 24 and through Week 100)

TREMFYA® (guselkumab) DISCOVER 2 patient retention data

Reasons for discontinuation included: adverse event, lack of efficacy, withdrawn consent, lost to follow-up, death, and other.

No conclusions regarding clinical efficacy or safety can be drawn.

*Year 2 represents Week 100.

Patient retention data in DISCOVER 2 (Week 24 and through Week 100) and in DISCOVER 1 (Week 24 and prior to Week 48)^1*

Patient Retention Data in DISCOVER 2
(Week 24 and through Week 100)

TREMFYA® (guselkumab) DISCOVER 1 and DISCOVER 2 patient retention data

No conclusions regarding clinical efficacy or safety can be drawn.

^†Discontinuations shown for patients who were randomized and received at least 1 study drug administration.

^‡248 patients in DISCOVER 2 were randomized to TREMFYA^® 100 mg q8w dosing regimen through Week 112; TREMFYA^® q4w was not an FDA-approved dosing regimen.

^§1 patient-initiated, protocol-prohibited medication in the placebo group through Week 24.

Reference: 1. Data on file. Janssen Biotech, Inc.

See the TREMFYA® patient Retention data

~90% patient retention through 2 years with TREMFYA®1*

Patient retention data in DISCOVER 2 (Week 24 and through Week 100) and in DISCOVER 1 (Week 24 and prior to Week 48)1*

See the TREMFYA^® patient Retention data

~90% patient retention through 2 years with TREMFYA^®1*

Patient retention data in DISCOVER 2 (Week 24 and through Week 100) and in DISCOVER 1 (Week 24 and prior to Week 48)^1*